EMA has proposed to change the agency’s guideline for investigating drug interactions.
EMA states that studying drug interactions is growing more important as the European population ages, with more patients taking multiple drugs simultaneously.
The following items have been identified and would need to be addressed in the revised guideline:
1. New recommendations on:
– Inhibition and induction of enzymes in the intestine: specifying cutoffs for poorly soluble drugs.